The FDA’s Experience with Emerging Genomics Technologies—Past, Present, and Future

被引:0
作者
Joshua Xu
Shraddha Thakkar
Binsheng Gong
Weida Tong
机构
[1] U.S. Food and Drug Administration,Division of Bioinformatics and Biostatistics, National Center for Toxicological Research
来源
The AAPS Journal | 2016年 / 18卷
关键词
big data; genomics; next-generation sequencing; reproducibility; RNA-seq;
D O I
暂无
中图分类号
学科分类号
摘要
The rapid advancement of emerging genomics technologies and their application for assessing safety and efficacy of FDA-regulated products require a high standard of reliability and robustness supporting regulatory decision-making in the FDA. To facilitate the regulatory application, the FDA implemented a novel data submission program, Voluntary Genomics Data Submission (VGDS), and also to engage the stakeholders. As part of the endeavor, for the past 10 years, the FDA has led an international consortium of regulatory agencies, academia, pharmaceutical companies, and genomics platform providers, which was named MicroArray Quality Control Consortium (MAQC), to address issues such as reproducibility, precision, specificity/sensitivity, and data interpretation. Three projects have been completed so far assessing these genomics technologies: gene expression microarrays, whole genome genotyping arrays, and whole transcriptome sequencing (i.e., RNA-seq). The resultant studies provide the basic parameters for fit-for-purpose application of these new data streams in regulatory environments, and the solutions have been made available to the public through peer-reviewed publications. The latest MAQC project is also called the SEquencing Quality Control (SEQC) project focused on next-generation sequencing. Using reference samples with built-in controls, SEQC studies have demonstrated that relative gene expression can be measured accurately and reliably across laboratories and RNA-seq platforms. Besides prediction performance comparable to microarrays in clinical settings and safety assessments, RNA-seq is shown to have better sensitivity for low expression and reveal novel transcriptomic features. Future effort of MAQC will be focused on quality control of whole genome sequencing and targeted sequencing.
引用
收藏
页码:814 / 818
页数:4
相关论文
共 169 条
  • [1] Goodsaid FM(2010)Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact Nat Rev Drug Discov 9 435-45
  • [2] Amur S(2007)An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA’s critical path initiative Drug Discov Today Technol 4 3-8
  • [3] Aubrecht J(2015)Genomics in the land of regulatory science Regul Toxicol Pharmacol 72 102-6
  • [4] Burczynski ME(2010)The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models Nat Biotechnol 28 827-38
  • [5] Carl K(2010)An interactive effect of batch size and composition contributes to discordant results in GWAS with the CHIAMO genotyping algorithm Pharmacogenomics J 10 355-63
  • [6] Catalano J(2010)Consistency of predictive signature genes and classifiers generated using different microarray platforms Pharmacogenomics J 10 247-57
  • [7] Tong W(2010)Assessing sources of inconsistencies in genotypes and their effects on genome-wide association studies with HapMap samples Pharmacogenomics J 10 364-74
  • [8] Harris SC(2010)Genomic indicators in the blood predict drug-induced liver injury Pharmacogenomics J 10 267-77
  • [9] Fang H(2010)A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data Pharmacogenomics J 10 278-91
  • [10] Shi L(2010)Variability in GWAS analysis: the impact of genotype calling algorithm inconsistencies Pharmacogenomics J 10 324-35